V0116 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses V0116 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- V0116 transdermal patch (Test treatment )
- 2
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses V0116 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Nicotine Patch Safety StudyCompletedPhase 2Pierre Fabre MedicamentNCT01655082Written as V0116 transdermal patch
- Nicotine Patch Bioequivalence StudyCompletedPhase 1Pierre Fabre MedicamentNCT01658202Written as V0116 transdermal patch (Test treatment )
- Nicotine Patch - Multidose Bioequivalence StudyCompletedPhase 1Pierre Fabre MedicamentNCT01658215Written as V0116 transdermal patch (Test treatment )